Scilex Company Stock (NASDAQ:SCLX)


RevenueOwnershipFinancialsChart

Previous Close

$0.96

52W Range

$0.73 - $2.63

50D Avg

$0.97

200D Avg

$1.31

Market Cap

$201.38M

Avg Vol (3M)

$1.34M

Beta

1.17

Div Yield

-

SCLX Company Profile


Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

113

IPO Date

Mar 05, 2021

Website

SCLX Performance


SCLX Financial Summary


Dec 23Dec 22Dec 21
Revenue$46.74M$38.03M$31.32M
Operating Income$-105.43M$-50.63M$-35.84M
Net Income$-114.33M$-23.36M$-88.42M
EBITDA$-105.43M$-46.67M$-32.06M
Basic EPS$-0.88$-0.17$-0.63
Diluted EPS$-0.88$-0.17$-0.63

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
AZNAstraZeneca PLC
LLYEli Lilly and Company
BIIBBiogen Inc.
ABBVAbbVie Inc.
MRKMerck & Co., Inc.
GSKGSK plc
AMGNAmgen Inc.
BMYBristol-Myers Squibb Company
GILDGilead Sciences, Inc.
NVSNovartis AG
SNYSanofi